Three ways that decentralized trial design strengthens the regulatory case for CNS devices (opens in new tab)

By Michael Young, Lindus The path to market for central nervous system (CNS) treatments and devices is brutal. Recruitment is slow, and patient burden is high, while multisite structures introduce rater and protocol variability that adds noise to endpoints. On top of that, regulatory expectations for novel technologies keep shifting. CNS drugs face a 5.9%… The post appeared first on .